Online first
Clinical vignette
Published online: 2024-11-26
Complications associated with accelerated 5-fluorouracil (5-Fu) infusion
1, 2
, 3
, 3
Abstract
Not available
Keywords: 5-Fu5-fluorouraciltoxicity
References
- Seifert P, Baker L, Reed M, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975; 36(1): 123–128, doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c.
- Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park). 1998; 12(10 Suppl 7): 19–22.
- Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol. 2003; 8(3): 132–138.
- van Ku, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5‐fluorouracil‐associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000; 6(12): 4705–4712.
- Piedbois P, Rougier P, Buyse M, et al. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1): 301–308.